• Supply and Licence Agreement heralds way for Personalised Cancer Treatments

News & Views

Supply and Licence Agreement heralds way for Personalised Cancer Treatments

Aug 13 2021

BioNTech Cell & Gene Therapies GmbH has reached a commercial agreement with Takara Bio for the use of certain patents relating to its RetroNectin® reagent, which also covers reliable supplies of the product.

Patents licensed to the Mainz-based German company are based on Takara Bio’s proprietary RetroNectin® method, which includes a technology for gene transduction to cells by retrovirus/lentivirus vector and expansion of T-cells with high efficiency.

BioNTech is allowed to use RetroNectin® for production of its cell & gene therapy products, therapies in which a patient’s T cells are genetically engineered to express a CAR for the treatment of multiple solid tumours.

The method is said to be one of the mostly used standard protocols utilised for “Engineered T-cell Therapy,” and Takara Bio is expecting higher sales growth following its recent worldwide promotional activities.

More information online


Digital Edition

Lab Asia 31.2 April 2024

April 2024

In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...

View all digital editions

Events

Microbiology Society Annual Conference 2024

Apr 08 2024 Edinburgh 2024

analytica 2024

Apr 09 2024 Munich, Germany

ChemBio Finland 2024

Apr 10 2024 Helsinki, Finland

Analytica Anacon India & IndiaLabExpo

Apr 15 2024 Mumbai, India

Analitika Expo 2024

Apr 16 2024 Moscow, Russia

View all events